Business News • PR NewsWire • New data in adults with obesity or who are overweight with comorbidities losing at least 5% body weight with Saxenda® (liraglutide [rDNA origin] injection) showed improvement in blood glucose, CV risk factors and quality of life outcomes

New data in adults with obesity or who are overweight with comorbidities losing at least 5% body weight with Saxenda® (liraglutide [rDNA origin] injection) showed improvement in blood glucose, CV risk factors and quality of life outcomes

New data in adults with obesity or who are overweight with comorbidities losing at least 5% body weight with Saxenda® (liraglutide [rDNA origin] injection) showed improvement in blood glucose, CV risk factors and quality of life outcomes

SAN DIEGO, March 7, 2015 /PRNewswire/ -- Today, new data from the phase 3a SCALE™ Obesity and Pre-diabetes trial were presented at The Endocrine Society's 97th Annual Meeting (ENDO), showing that adults with obesity or who are overweight with comorbidities who had lost...

View More : http://www.prnewswire.com/news-releases/new-data-in-adults-with-obesity-or-who-are-overweight-with-comorbidities-losing-...

Releted News by prnewswire

Big Banks Next: Data Behind Company Spinoffs Reveals Value Creation, finds The Edge and Deloitte

Global Ad Agency Team Detroit Brings Industry Leaders Together for South by Southwest (SXSW) Panel on Using Data to Create Rich User Experiences

KitchenAid® Precise Heat Mixing Bowl Simplifies Tricky and Traditional Cooking Techniques